<?xml version='1.0' encoding='utf-8'?>
<document id="30560314"><sentence text="Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination."><entity charOffset="36-56" id="DDI-PubMed.30560314.s1.e0" text="Olmesartan Medoxomil" /><entity charOffset="61-80" id="DDI-PubMed.30560314.s1.e1" text="Hydrochlorothiazide" /><pair ddi="false" e1="DDI-PubMed.30560314.s1.e0" e2="DDI-PubMed.30560314.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30560314.s1.e0" e2="DDI-PubMed.30560314.s1.e1" /></sentence><sentence text="Olmesartan medoxomil (Olm) and hydrochlorothiazide (HCTZ) are fixed dose combination (FDC) for treatment of hypertension"><entity charOffset="0-20" id="DDI-PubMed.30560314.s2.e0" text="Olmesartan medoxomil" /><entity charOffset="22-25" id="DDI-PubMed.30560314.s2.e1" text="Olm" /><entity charOffset="31-50" id="DDI-PubMed.30560314.s2.e2" text="hydrochlorothiazide" /><entity charOffset="52-56" id="DDI-PubMed.30560314.s2.e3" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e0" e2="DDI-PubMed.30560314.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e0" e2="DDI-PubMed.30560314.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e0" e2="DDI-PubMed.30560314.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e0" e2="DDI-PubMed.30560314.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e1" e2="DDI-PubMed.30560314.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e1" e2="DDI-PubMed.30560314.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e1" e2="DDI-PubMed.30560314.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e2" e2="DDI-PubMed.30560314.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30560314.s2.e2" e2="DDI-PubMed.30560314.s2.e3" /></sentence><sentence text=" They have hydrogen bonding sites and may interact during co-processing"><entity charOffset="11-19" id="DDI-PubMed.30560314.s3.e0" text="hydrogen" /></sentence><sentence text=" The consequences of such interaction are not clear" /><sentence text=" This study investigated the possibility of this interaction during co-processing" /><sentence text=" The research was extended to inhibit deleterious interactions" /><sentence text=" The drugs were co-evaporated from ethanolic solution to maximize the chance of interaction"><entity charOffset="35-44" id="DDI-PubMed.30560314.s7.e0" text="ethanolic" /></sentence><sentence text=" This was performed in the absence and presence of hydroxypropyl methylcellulose (HPMC) and/or aerosil" /><sentence text=" The products were characterized using Fourier transform infrared spectroscopy (FTIR), differential thermal analysis, and powder X-ray diffraction (PXRD) in addition to dissolution studies" /><sentence text=" Co-evaporation of Olm with HCTZ in the absence of excipients produced crystalline material with FTIR spectrum showing intermolecular hydrogen bonding"><entity charOffset="134-142" id="DDI-PubMed.30560314.s10.e0" text="hydrogen" /><entity charOffset="19-26" id="DDI-PubMed.30560314.s10.e1" text="Olm" /><entity charOffset="28-35" id="DDI-PubMed.30560314.s10.e2" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.30560314.s10.e1" e2="DDI-PubMed.30560314.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30560314.s10.e1" e2="DDI-PubMed.30560314.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30560314.s10.e1" e2="DDI-PubMed.30560314.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30560314.s10.e2" e2="DDI-PubMed.30560314.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30560314.s10.e2" e2="DDI-PubMed.30560314.s10.e0" /></sentence><sentence text=" This material showed thermal pattern of new crystalline species" /><sentence text=" This was identified as Olm/HCTZ co-crystal by PXRD"><entity charOffset="24-27" id="DDI-PubMed.30560314.s12.e0" text="Olm" /><entity charOffset="28-31" id="DDI-PubMed.30560314.s12.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.30560314.s12.e0" e2="DDI-PubMed.30560314.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30560314.s12.e0" e2="DDI-PubMed.30560314.s12.e1" /></sentence><sentence text=" This co-crystallization reduced the dissolution rate of both drugs" /><sentence text=" This co-crystallization was inhibited in the presence of HPMC, but the dissolution rate was not significantly enhanced accordingly" /><sentence text=" Co-processing in the presence of both HPMC and aerosil eliminated the co-crystallization and minimized the intermolecular drug-drug interaction with subsequent dissolution enhancement" /><sentence text=" The study introduced a composition for fixed dose combination of Olm and HCTZ with enhanced dissolution"><entity charOffset="66-69" id="DDI-PubMed.30560314.s16.e0" text="Olm" /><entity charOffset="74-77" id="DDI-PubMed.30560314.s16.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.30560314.s16.e0" e2="DDI-PubMed.30560314.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30560314.s16.e0" e2="DDI-PubMed.30560314.s16.e1" /></sentence><sentence text="" /></document>